| J07BD52 |
Measles, mumps and rubella vaccine (live) |
Priorix |
Powder and solvent for suspension for injection |
1 dose 0.5 ml |
|
100 vial with powder + 100 ampoule with solvent |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
1872 |
18.66 |
1866 |
100% |
|
Съгласно РУ |
НСР-8093/17.02.2016. |
02.03.2016 |
|
Активен |
4184 |
| J07BF02 |
Poliomyelitis vaccine, (live attenuated) |
J07BF02 Poliomyelitis vaccine, (live attenuated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BF02 |
Poliomyelitis vaccine, (live attenuated) |
POLIO SABIN (ORAL) |
Oral drops, suspension |
10 doses (1 ml) |
|
100 vial + dropper applicator |
ГлаксоСмитКлайн ЕООД, България |
1 |
dose |
798.24 |
0.79824 |
798.24 |
100% |
|
Съгласно РУ |
№ 25/03.08.2009.; НСР-12997/15.06.2017 |
02.07.2017 |
08.09.2012 |
Заличен |
687 |
| J07BF03 |
Poliomyelitis vaccine, inactivated |
J07BF03 Poliomyelitis vaccine, inactivated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BF03 |
Poliomyelitis vaccine, inactivated |
Poliorix |
Solution for injection |
0.5 ml (1dose) |
|
1 vial |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
17.46 |
17.46 |
17.46 |
100% |
|
Съгласно РУ |
НСР-16756/07.09.2018 |
02.10.2018 |
08.09.2012 |
Заличен |
128 |
| J07BH01 |
Rotavirus vaccine, live |
J07BH01 Rotavirus vaccine, live |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BH01 |
Rota virus, live attenuated |
Rotarix |
Powder and solvent for oral suspension |
Human rotavirus RIX4414 strain (live, attenuated) ≥ 106.0 CCID50 |
mg |
1 |
GlaxoSmithKline Biologicals S.A., Белгия |
|
- |
122.04 |
|
122.04 |
100% |
|
Съгласно РУ |
|
|
08.09.2012 |
Заличен |
135 |
| J07BH01 |
Rotavirus vaccine, live |
J07BH01 Rotavirus vaccine, live |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BH01 |
Rota virus, live attenuated |
ROTARIX |
Oral suspension |
1.5 ml prefilled oral applicator (glass) |
|
1 dose |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
101.46 |
101.46 |
101.46 |
100% |
|
Съгласно РУ |
№ 180/ 27.07.2011; НСР-4593/15.09.2014; НСР-6181/08.05.2015; НСР-13340/28.07.2017; НСР-17029/19.10.2018; НСР-19058/27.06.2019 |
02.08.2019 |
08.09.2012 |
Активен |
3932 |
| J07BM01 |
(Human papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)) Адсорбирана ваксина срещу човешки папиломавирус [Тип 6, 11, 16, 18] (рекомбинанта) |
J07BM01 (Human papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)) Адсорбирана ваксина срещу човешки папиломавирус [Тип 6, 11, 16, 18] (рекомбинанта) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BM01 |
Papillomavirus (human types 6, 11, 16, 18) |
SILGARD |
Suspension for injection |
0,5 ml |
|
1 pre-filled syringe + 2 needles |
Merck Sharp & Dohme Ltd., Обединено Кралство |
1 |
dose |
211.62 |
211.62 |
211.62 |
100% |
|
Съгласно РУ |
№ 14/19.06.2009 г.; КЦРР-742/07.06.2012 г.; КЦРР-1735/04.12.2012 г; НСР-18722/20.05.2019 |
02.07.2019 |
08.09.2012 |
Заличен |
1501 |
| J07BM02 |
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) |
J07BM02 Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07BM02 |
Papillomavirus (Human Types 16, 18) |
Cervarix |
Suspension for injection |
1 dose (0,5 ml) |
|
1 pre-filled syringe + 2 needles |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
110.94 |
110.94 |
110.94 |
100% |
|
Съгласно РУ |
КЦРР-1734/04.12.2012 г; НСР-3176/07.04.2014 |
02.05.2014 |
08.09.2012 |
Активен |
2683 |
| J07CA02 |
Diphteria, tetanus, pertussis (acellular, component) and Poliomyelitis (inactivated) vaccine (adsorbed) |
J07CA02 Diphteria, tetanus, pertussis (acellular, component) and Poliomyelitis (inactivated) vaccine (adsorbed) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA02 |
diphtheria-pertussis-poliomyelitis-tetanus |
Boostrix polio |
Suspension for injection |
1 dose(0,5 ml) |
|
1 pre-filled syringe + 1 needle |
ГлаксоСмитКлайн ЕООД, България |
1 |
dose |
42.06 |
42.06 |
42.06 |
100% |
|
Съгласно РУ |
КЦРР-1673/20.11.2012 г.; НСР-2753/17.02.2014; НСР-5459/16.01.2015 |
16.02.2015 |
|
Активен |
3515 |
| J07CA06 |
Diphteria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilis type b conjugate vaccine (adsorbed) |
J07CA06 Diphteria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilis type b conjugate vaccine (adsorbed) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA06 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus |
Infanrix-IPV+HIB |
Powder and suspension for suspension for injection |
|
|
1 vial + 1 pre-filled syringe 0.5 ml + 2 needles |
ГлаксоСмитКлайн ЕООД, България |
1 |
dose |
45.91 |
45.91 |
45.91 |
100% |
|
Съгласно РУ |
№ 44/07.01.2010 г.; № 57/05.03.2010 г.; КЦРР-2541/14.03.2013 г.; НСР-4994/05.11.2014; НСР-6674/09.07.2015; НСР-8326/26.02.2016 |
02.04.2016 |
08.09.2012 |
Активен |
3339 |
| J07CA09 |
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) |
J07CA09 Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
0.5 |
ml |
1 vial + 1 pre-filled syringe without needle |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
71.27 |
71.27 |
71.27 |
100% |
|
Съгласно РУ |
НСР-15129/02.03.2018 |
02.04.2018 |
|
Активен |
16058 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
suspension: 0.5 ml |
|
1 vial + 1 prefilled syringe + 2 needles |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
71.27 |
71.27 |
71.27 |
100% |
|
Съгласно РУ |
КЦРР-2406/21.02.2013 г.; НСР-7707/17.12.2015, Протокол № 227/01.06.2017 |
02.07.2017 |
08.09.2012 |
Активен |
1754 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
0.5 |
ml |
10 vials+10 prefilled syringes+20 needles |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
831.83 |
71.27 |
712.7 |
100% |
|
Съгласно РУ |
НСР-15129/02.03.2018; НСР-19003/20.06.2019 |
02.08.2019 |
|
Активен |
16057 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Infanrix Hexa |
Powder and suspension for suspension for injection |
suspension: 0.5 ml |
|
10 vials + 10 prefilled syringes |
GlaxoSmithKline Biologicals S.A., Белгия |
1 |
dose |
831.83 |
71.27 |
712.7 |
100% |
|
Съгласно РУ |
НСР-4827/14.10.2014, Протокол № 231/29.06.2017; НСР-18886/06.06.2019 |
02.07.2019 |
|
Активен |
3213 |
| J07CA09 |
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) |
J07CA09 Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Hexacima |
Suspension for injection |
0,5 ml |
|
1 pre-filled syringe + 2 needles |
Sanofi Pasteur S.A., Франция |
1 |
dose |
72.01 |
72.01 |
72.01 |
100% |
|
Съгласно РУ |
НСР-3659/29.05.2014; НСР-5521/29.01.2015.; НСР-8627/31.03.2016. |
02.03.2018 |
|
Активен |
3537 |
| J07CA09 |
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
Hexacima |
Suspension for injection |
0,5 ml |
|
10 vials (glass) |
Sanofi Pasteur S.A., Франция |
1 |
dose |
895.06 |
72.01 |
720.1 |
100% |
|
Съгласно РУ |
НСР-4954/27.10.2014; НСР-19127/04.07.2019;НСР-19132/04.07.2019 |
02.08.2019 |
|
Заличен |
3228 |
